Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 19 entries
Sorted by: Best Match Show Resources per page
Enzyme-Free Immunoassay Using Silver Nanoparticles for Detection of Gliadin at Ultralow Concentrations.

ACS omega

Mercadal PA, Fraire JC, Motrich RD, Coronado EA.
PMID: 31458532
ACS Omega. 2018 Feb 27;3(2):2340-2350. doi: 10.1021/acsomega.7b01840. eCollection 2018 Feb 28.

Determination of biomarkers in clinical or food samples is of crucial importance for monitoring, prevention, and care of public health. The standard procedure used for this purpose is the enzyme-linked immunosorbent assay (ELISA), which makes use of the specific...

Cite
Mercadal PA, Fraire JC, Motrich RD, et al. Enzyme-Free Immunoassay Using Silver Nanoparticles for Detection of Gliadin at Ultralow Concentrations. ACS Omega. 2018;3(2):2340-2350doi: 10.1021/acsomega.7b01840.
Mercadal, P. A., Fraire, J. C., Motrich, R. D., & Coronado, E. A. (2018). Enzyme-Free Immunoassay Using Silver Nanoparticles for Detection of Gliadin at Ultralow Concentrations. ACS omega, 3(2), 2340-2350. https://doi.org/10.1021/acsomega.7b01840
Mercadal, Pablo A, et al. "Enzyme-Free Immunoassay Using Silver Nanoparticles for Detection of Gliadin at Ultralow Concentrations." ACS omega vol. 3,2 (2018): 2340-2350. doi: https://doi.org/10.1021/acsomega.7b01840
Mercadal PA, Fraire JC, Motrich RD, Coronado EA. Enzyme-Free Immunoassay Using Silver Nanoparticles for Detection of Gliadin at Ultralow Concentrations. ACS Omega. 2018 Feb 27;3(2):2340-2350. doi: 10.1021/acsomega.7b01840. eCollection 2018 Feb 28. PMID: 31458532; PMCID: PMC6641231.
Copy Download .nbib Format: NLM
Measuring Family Relations: Italian Validation of the "Cuestionario de Evaluación de Las Relaciones Familiares Básicas" (CERFB).

Clinical neuropsychiatry

Vilaregut A, Callea A, Campreciós M, Coletti M, Mercadal L, Mateu C.
PMID: 34908945
Clin Neuropsychiatry. 2019 Apr;16(2):116-123.

OBJECTIVE: In recent years, the gap between research into family therapy and clinical practice in the field has been growing larger. In the Italian context, a major issue concerns the lack of any single instrument that can be used...

Cite
Vilaregut A, Callea A, Campreciós M, et al. Measuring Family Relations: Italian Validation of the "Cuestionario de Evaluación de Las Relaciones Familiares Básicas" (CERFB). Clin Neuropsychiatry. 2019;16(2):116-123
Vilaregut, A., Callea, A., Campreciós, M., Coletti, M., Mercadal, L., & Mateu, C. (2019). Measuring Family Relations: Italian Validation of the "Cuestionario de Evaluación de Las Relaciones Familiares Básicas" (CERFB). Clinical neuropsychiatry, 16(2), 116-123.
Vilaregut, Anna, et al. "Measuring Family Relations: Italian Validation of the "Cuestionario de Evaluación de Las Relaciones Familiares Básicas" (CERFB)." Clinical neuropsychiatry vol. 16,2 (2019): 116-123.
Vilaregut A, Callea A, Campreciós M, Coletti M, Mercadal L, Mateu C. Measuring Family Relations: Italian Validation of the "Cuestionario de Evaluación de Las Relaciones Familiares Básicas" (CERFB). Clin Neuropsychiatry. 2019 Apr;16(2):116-123. PMID: 34908945; PMCID: PMC8650185.
Copy Download .nbib Format: NLM
Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.

British journal of haematology

Dlouhy I, Karube K, Enjuanes A, Salaverria I, Nadeu F, Ramis-Zaldivar JE, Valero JG, Rivas-Delgado A, Magnano L, Martin-García D, Pérez-Galán P, Clot G, Rovira J, Jares P, Balagué O, Giné E, Mozas P, Briones J, Sancho JM, Salar A, Mercadal S, Alcoceba M, Valera A, Campo E, López-Guillermo A.
PMID: 34632572
Br J Haematol. 2021 Oct 10; doi: 10.1111/bjh.17858. Epub 2021 Oct 10.

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) cases have a poor outcome. Here we analysed clinico-biological features in 373 DLBCL patients homogeneously treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP), in order to identify variables associated with...

Cite
Dlouhy I, Karube K, Enjuanes A, et al. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. Br J Haematol. 2021;doi: 10.1111/bjh.17858.
Dlouhy, I., Karube, K., Enjuanes, A., Salaverria, I., Nadeu, F., Ramis-Zaldivar, J. E., Valero, J. G., Rivas-Delgado, A., Magnano, L., Martin-García, D., Pérez-Galán, P., Clot, G., Rovira, J., Jares, P., Balagué, O., Giné, E., Mozas, P., Briones, J., Sancho, J. M., Salar, A., Mercadal, S., Alcoceba, M., Valera, A., Campo, E., & López-Guillermo, A. (2021). Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. British journal of haematology, . https://doi.org/10.1111/bjh.17858
Dlouhy, Ivan, et al. "Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17858
Dlouhy I, Karube K, Enjuanes A, Salaverria I, Nadeu F, Ramis-Zaldivar JE, Valero JG, Rivas-Delgado A, Magnano L, Martin-García D, Pérez-Galán P, Clot G, Rovira J, Jares P, Balagué O, Giné E, Mozas P, Briones J, Sancho JM, Salar A, Mercadal S, Alcoceba M, Valera A, Campo E, López-Guillermo A. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma. Br J Haematol. 2021 Oct 10; doi: 10.1111/bjh.17858. Epub 2021 Oct 10. PMID: 34632572.
Copy Download .nbib Format: NLM
Recurrent pneumonia and colobronchial fistula from Crohn's disease: Infliximab alters and simplifies surgical management.

Annals of gastroenterology

Mercadal NR, Wiebke EA.
PMID: 24714263
Ann Gastroenterol. 2012;25(4):361-364.

We report a rare case of right-sided colobronchial fistula in a 47-year-old, severely malnourished male with a history of regional enteritis and recurrent right lower and middle lobe pneumonias medically managed with the addition of the immunomodulator infliximab prior...

Cite
Mercadal NR, Wiebke EA. Recurrent pneumonia and colobronchial fistula from Crohn's disease: Infliximab alters and simplifies surgical management. Ann Gastroenterol. 2012;25(4):361-364
Mercadal, N. R., & Wiebke, E. A. (2012). Recurrent pneumonia and colobronchial fistula from Crohn's disease: Infliximab alters and simplifies surgical management. Annals of gastroenterology, 25(4), 361-364.
Mercadal, Nuria Rosa, and Wiebke, Eric A. "Recurrent pneumonia and colobronchial fistula from Crohn's disease: Infliximab alters and simplifies surgical management." Annals of gastroenterology vol. 25,4 (2012): 361-364.
Mercadal NR, Wiebke EA. Recurrent pneumonia and colobronchial fistula from Crohn's disease: Infliximab alters and simplifies surgical management. Ann Gastroenterol. 2012;25(4):361-364. PMID: 24714263; PMCID: PMC3959410.
Copy Download .nbib Format: NLM
Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy.

Clinical medicine insights. Blood disorders

Mercadal S, Climent F, Domingo-Doménech E, Oliveira A, Romagosa V, de Sevilla AF, González-Barca E.
PMID: 25512717
Clin Med Insights Blood Disord. 2013 Nov 14;6:23-7. doi: 10.4137/CMBD.S12713. eCollection 2013.

Diffuse large b-cell lymphoma (DLBCL) is an aggressive and potentially curable lymphoma that presents itself as stage I-II in 30% of all cases. It is known that in these localized stages, 15-20% of patients treated without rituximab eventually relapse,...

Cite
Mercadal S, Climent F, Domingo-Doménech E, et al. Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. Clin Med Insights Blood Disord. 2013;6:23-7doi: 10.4137/CMBD.S12713.
Mercadal, S., Climent, F., Domingo-Doménech, E., Oliveira, A., Romagosa, V., de Sevilla, A. F., & González-Barca, E. (2013). Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. Clinical medicine insights. Blood disorders, 623-7. https://doi.org/10.4137/CMBD.S12713
Mercadal, S, et al. "Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy." Clinical medicine insights. Blood disorders vol. 6 (2013): 23-7. doi: https://doi.org/10.4137/CMBD.S12713
Mercadal S, Climent F, Domingo-Doménech E, Oliveira A, Romagosa V, de Sevilla AF, González-Barca E. Clinical Characteristics and Risk of Relapse for Patients with Stage I-II Diffuse Large B-cell Lymphoma Treated in First Line with Immunochemotherapy. Clin Med Insights Blood Disord. 2013 Nov 14;6:23-7. doi: 10.4137/CMBD.S12713. eCollection 2013. PMID: 25512717; PMCID: PMC4222304.
Copy Download .nbib Format: NLM
How to define a cut-off value of tumour markers in haemodialysis patients?.

NDT plus

Mercadal L, Cormont S, Tezenas-du-Montcel S, Hacini S, Venditto M, Deray G.
PMID: 25949331
NDT Plus. 2009 Apr;2(2):188-9. doi: 10.1093/ndtplus/sfn216.

No abstract available.

Cite
Mercadal L, Cormont S, Tezenas-du-Montcel S, et al. How to define a cut-off value of tumour markers in haemodialysis patients?. NDT Plus. 2009;2(2):188-9doi: 10.1093/ndtplus/sfn216.
Mercadal, L., Cormont, S., Tezenas-du-Montcel, S., Hacini, S., Venditto, M., & Deray, G. (2009). How to define a cut-off value of tumour markers in haemodialysis patients?. NDT plus, 2(2), 188-9. https://doi.org/10.1093/ndtplus/sfn216
Mercadal, Lucile, et al. "How to define a cut-off value of tumour markers in haemodialysis patients?." NDT plus vol. 2,2 (2009): 188-9. doi: https://doi.org/10.1093/ndtplus/sfn216
Mercadal L, Cormont S, Tezenas-du-Montcel S, Hacini S, Venditto M, Deray G. How to define a cut-off value of tumour markers in haemodialysis patients?. NDT Plus. 2009 Apr;2(2):188-9. doi: 10.1093/ndtplus/sfn216. PMID: 25949331; PMCID: PMC4421335.
Copy Download .nbib Format: NLM
Modeling methods for treatment planning in overlapping electroporation treatments.

IEEE transactions on bio-medical engineering

Perera-Bel E, Mercadal B, Garcia-Sanchez T, Gonzalez Ballester MA, Ivorra A.
PMID: 34559631
IEEE Trans Biomed Eng. 2021 Sep 24; doi: 10.1109/TBME.2021.3115029. Epub 2021 Sep 24.

OBJECTIVE: Irreversible electroporation (IRE) is a non thermal tissue ablation therapy which is induced by applying high voltage waveforms across electrode pairs. When multiple electrode pairs are sequentially used, the treatment volume (TV) is typically computed as the geometric...

Cite
Perera-Bel E, Mercadal B, Garcia-Sanchez T, et al. Modeling methods for treatment planning in overlapping electroporation treatments. IEEE Trans Biomed Eng. 2021;doi: 10.1109/TBME.2021.3115029.
Perera-Bel, E., Mercadal, B., Garcia-Sanchez, T., Gonzalez Ballester, M. A., & Ivorra, A. (2021). Modeling methods for treatment planning in overlapping electroporation treatments. IEEE transactions on bio-medical engineering, . https://doi.org/10.1109/TBME.2021.3115029
Perera-Bel, Enric, et al. "Modeling methods for treatment planning in overlapping electroporation treatments." IEEE transactions on bio-medical engineering vol. (2021). doi: https://doi.org/10.1109/TBME.2021.3115029
Perera-Bel E, Mercadal B, Garcia-Sanchez T, Gonzalez Ballester MA, Ivorra A. Modeling methods for treatment planning in overlapping electroporation treatments. IEEE Trans Biomed Eng. 2021 Sep 24; doi: 10.1109/TBME.2021.3115029. Epub 2021 Sep 24. PMID: 34559631.
Copy Download .nbib Format: NLM
A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection.

Bone marrow transplantation

Parody R, Sánchez-Ortega I, Mussetti A, Patiño B, Arnan M, Pomares H, González-Barca E, Mercadal S, Boqué C, Maluquer C, Carro I, Peña M, Clapés V, Verdesoto S, Bustamante G, Oliveira AC, Baca C, Cabezudo E, Talarn C, Escoda L, Ortega S, García N, Isabel González-Medina M, Sánchez-Salmerón M, Fusté C, Villa J, Carreras E, Domingo-Domènech E, Sureda A.
PMID: 34711917
Bone Marrow Transplant. 2021 Oct 28; doi: 10.1038/s41409-021-01506-4. Epub 2021 Oct 28.

Traceability of patients who are candidates for Hematopoietic cell transplant (HCT) is crucial to ensure HCT program quality. Continuous knowledge of both a detailed registry from a HCT program and final exclusion causes can contribute to promoting a real-life...

Cite
Parody R, Sánchez-Ortega I, Mussetti A, et al. A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. Bone Marrow Transplant. 2021;doi: 10.1038/s41409-021-01506-4.
Parody, R., Sánchez-Ortega, I., Mussetti, A., Patiño, B., Arnan, M., Pomares, H., González-Barca, E., Mercadal, S., Boqué, C., Maluquer, C., Carro, I., Peña, M., Clapés, V., Verdesoto, S., Bustamante, G., Oliveira, A. C., Baca, C., Cabezudo, E., Talarn, C., Escoda, L., Ortega, S., García, N., Isabel González-Medina, M., Sánchez-Salmerón, M., Fusté, C., Villa, J., Carreras, E., Domingo-Domènech, E., & Sureda, A. (2021). A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. Bone marrow transplantation, . https://doi.org/10.1038/s41409-021-01506-4
Parody, R, et al. "A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection." Bone marrow transplantation vol. (2021). doi: https://doi.org/10.1038/s41409-021-01506-4
Parody R, Sánchez-Ortega I, Mussetti A, Patiño B, Arnan M, Pomares H, González-Barca E, Mercadal S, Boqué C, Maluquer C, Carro I, Peña M, Clapés V, Verdesoto S, Bustamante G, Oliveira AC, Baca C, Cabezudo E, Talarn C, Escoda L, Ortega S, García N, Isabel González-Medina M, Sánchez-Salmerón M, Fusté C, Villa J, Carreras E, Domingo-Domènech E, Sureda A. A real-life overview of a hematopoietic cell transplant program throughout a four-year period, including prospective registry, exclusion causes and final donor selection. Bone Marrow Transplant. 2021 Oct 28; doi: 10.1038/s41409-021-01506-4. Epub 2021 Oct 28. PMID: 34711917.
Copy Download .nbib Format: NLM
A randomized phase II study comparing consolidation with a single dose of .

Leukemia & lymphoma

López-Guillermo A, Canales MÁ, Dlouhy I, Mercadal S, Briones J, Martín García-Sancho A, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, López A, Panizo C, Muntañola A, Montalbán C, Conde E, Hernández MT, Soler A, García Marco JA, Deben G, Marín J, Tomás JF.
PMID: 34459702
Leuk Lymphoma. 2022 Jan;63(1):93-100. doi: 10.1080/10428194.2021.1971216. Epub 2021 Aug 30.

This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.gov #NCT00662948). Patients in PR or CR/CR[u] after...

Cite
López-Guillermo A, Canales MÁ, Dlouhy I, et al. A randomized phase II study comparing consolidation with a single dose of . Leuk Lymphoma. 2021;63(1):93-100doi: 10.1080/10428194.2021.1971216.
López-Guillermo, A., Canales, M. �. �., Dlouhy, I., Mercadal, S., Briones, J., Martín García-Sancho, A., Sancho, J. M., Moraleda, J. M., Terol, M. J., Salar, A., Palomera, L., Gardella, S., Jarque, I., Ferrer, S., Bargay, J., López, A., Panizo, C., Muntañola, A., Montalbán, C., Conde, E., Hernández, M. T., Soler, A., García Marco, J. A., Deben, G., Marín, J., Tomás, J. F. (2022). A randomized phase II study comparing consolidation with a single dose of . Leukemia & lymphoma, 63(1), 93-100. https://doi.org/10.1080/10428194.2021.1971216
López-Guillermo, Armando, et al. "A randomized phase II study comparing consolidation with a single dose of ." Leukemia & lymphoma vol. 63,1 (2022): 93-100. doi: https://doi.org/10.1080/10428194.2021.1971216
López-Guillermo A, Canales MÁ, Dlouhy I, Mercadal S, Briones J, Martín García-Sancho A, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, López A, Panizo C, Muntañola A, Montalbán C, Conde E, Hernández MT, Soler A, García Marco JA, Deben G, Marín J, Tomás JF. A randomized phase II study comparing consolidation with a single dose of . Leuk Lymphoma. 2022 Jan;63(1):93-100. doi: 10.1080/10428194.2021.1971216. Epub 2021 Aug 30. PMID: 34459702.
Copy Download .nbib Format: NLM
Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols.

British journal of haematology

Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, González-Campos J, Tormo M, García-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermúdez A, Orfao A, Ribera JM.
PMID: 34549416
Br J Haematol. 2021 Sep 21; doi: 10.1111/bjh.17844. Epub 2021 Sep 21.

The prognosis of t(1;19)(q23;p13)/transcription factor 3-pre-B-cell leukaemia homeobox 1 (TCF3-PBX1) in adolescent and adult patients with acute lymphoblastic leukaemia (ALL) treated with measurable residual disease (MRD)-oriented trials remains controversial. In the present study, we analysed the outcome of adolescent...

Cite
Ribera J, Granada I, Morgades M, et al. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Br J Haematol. 2021;doi: 10.1111/bjh.17844.
Ribera, J., Granada, I., Morgades, M., González, T., Ciudad, J., Such, E., Calasanz, M. J., Mercadal, S., Coll, R., González-Campos, J., Tormo, M., García-Cadenas, I., Gil, C., Cervera, M., Barba, P., Costa, D., Ayala, R., Bermúdez, A., Orfao, A., Ribera, J. M. (2021). Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. British journal of haematology, . https://doi.org/10.1111/bjh.17844
Ribera, Jordi, et al. "Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols." British journal of haematology vol. (2021). doi: https://doi.org/10.1111/bjh.17844
Ribera J, Granada I, Morgades M, González T, Ciudad J, Such E, Calasanz MJ, Mercadal S, Coll R, González-Campos J, Tormo M, García-Cadenas I, Gil C, Cervera M, Barba P, Costa D, Ayala R, Bermúdez A, Orfao A, Ribera JM. Prognostic heterogeneity of adult B-cell precursor acute lymphoblastic leukaemia patients with t(1;19)(q23;p13)/TCF3-PBX1 treated with measurable residual disease-oriented protocols. Br J Haematol. 2021 Sep 21; doi: 10.1111/bjh.17844. Epub 2021 Sep 21. PMID: 34549416.
Copy Download .nbib Format: NLM
Vascular access cannulation and haemostasis: a national observational study of French practices.

Clinical kidney journal

Sallée M, Mercadal L, Jean G, Guery B, Borniche D, Charrel JM, Hannedouche T, Roy FL, Brunet P.
PMID: 33841870
Clin Kidney J. 2020 Oct 02;14(4):1261-1268. doi: 10.1093/ckj/sfaa098. eCollection 2021 Apr.

BACKGROUND: We report the results of an observational study of arteriovenous fistula (AVF) cannulation and haemostasis practices in France.METHODS: The study (sponsored by Brothier Pharmaceutical Inc.) was conducted in 150 dialysis units. Data obtained from 150 supervisory nurses, 1538...

Cite
Sallée M, Mercadal L, Jean G, et al. Vascular access cannulation and haemostasis: a national observational study of French practices. Clin Kidney J. 2020;14(4):1261-1268doi: 10.1093/ckj/sfaa098.
Sallée, M., Mercadal, L., Jean, G., Guery, B., Borniche, D., Charrel, J. M., Hannedouche, T., Roy, F. L., & Brunet, P. (2021). Vascular access cannulation and haemostasis: a national observational study of French practices. Clinical kidney journal, 14(4), 1261-1268. https://doi.org/10.1093/ckj/sfaa098
Sallée, Marion, et al. "Vascular access cannulation and haemostasis: a national observational study of French practices." Clinical kidney journal vol. 14,4 (2021): 1261-1268. doi: https://doi.org/10.1093/ckj/sfaa098
Sallée M, Mercadal L, Jean G, Guery B, Borniche D, Charrel JM, Hannedouche T, Roy FL, Brunet P. Vascular access cannulation and haemostasis: a national observational study of French practices. Clin Kidney J. 2020 Oct 02;14(4):1261-1268. doi: 10.1093/ckj/sfaa098. eCollection 2021 Apr. PMID: 33841870; PMCID: PMC8023177.
Copy Download .nbib Format: NLM
Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients.

Clinical kidney journal

Desbuissons G, Izzedine H, Bardier A, Dubreuil O, Vaillant JC, Frochot V, Mercadal L.
PMID: 31807294
Clin Kidney J. 2019 Feb 18;12(6):821-828. doi: 10.1093/ckj/sfz015. eCollection 2019 Dec.

BACKGROUND: Despite new therapeutics, the prognosis for pancreatic cancer remains poor. Pancreatic surgery is a therapeutic option in non-metastatic forms. The consequences for renal function are poorly described.METHODS: Patients who underwent surgery for pancreatic cancer between 1 January 2010...

Cite
Desbuissons G, Izzedine H, Bardier A, et al. Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients. Clin Kidney J. 2019;12(6):821-828doi: 10.1093/ckj/sfz015.
Desbuissons, G., Izzedine, H., Bardier, A., Dubreuil, O., Vaillant, J. C., Frochot, V., & Mercadal, L. (2019). Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients. Clinical kidney journal, 12(6), 821-828. https://doi.org/10.1093/ckj/sfz015
Desbuissons, Geoffroy, et al. "Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients." Clinical kidney journal vol. 12,6 (2019): 821-828. doi: https://doi.org/10.1093/ckj/sfz015
Desbuissons G, Izzedine H, Bardier A, Dubreuil O, Vaillant JC, Frochot V, Mercadal L. Oxalate nephropathy is a major cause of kidney injury in surgically treated pancreatic adenocarcinoma patients. Clin Kidney J. 2019 Feb 18;12(6):821-828. doi: 10.1093/ckj/sfz015. eCollection 2019 Dec. PMID: 31807294; PMCID: PMC6885689.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 19 entries